Literature DB >> 23910691

Serum levels of bone cytokines are increased in indolent systemic mastocytosis associated with osteopenia or osteoporosis.

Anja Rabenhorst1, Bastian Christopeit, Silke Leja, Alexander Gerbaulet, Svea Kleiner, Anja Förster, Ulrike Raap, Claudia Wickenhauser, Karin Hartmann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 23910691     DOI： 10.1016/j.jaci.2013.06.019

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN： 0091-6749            Impact factor:   10.793


× No keyword cloud information.
  18 in total

1.  Increased IL6 plasma levels in indolent systemic mastocytosis patients are associated with high risk of disease progression.

Authors:  A Mayado; C Teodosio; A C Garcia-Montero; A Matito; A Rodriguez-Caballero; J M Morgado; C Muñiz; M Jara-Acevedo; I Álvarez-Twose; L Sanchez-Muñoz; S Matarraz; C Caldas; J I Muñoz-González; L Escribano; A Orfao
Journal:  Leukemia       Date:  2015-07-08       Impact factor: 11.528

Review 2.  Management of endocrine disease: Secondary osteoporosis: pathophysiology and management.

Authors:  Faryal Mirza; Ernesto Canalis
Journal:  Eur J Endocrinol       Date:  2015-05-13       Impact factor: 6.664

3.  CCL2 is a KIT D816V-dependent modulator of the bone marrow microenvironment in systemic mastocytosis.

Authors:  Georg Greiner; Nadine Witzeneder; Angelika Berger; Klaus Schmetterer; Gregor Eisenwort; Ana-Iris Schiefer; Simone Roos; Theresia Popow-Kraupp; Leonhard Müllauer; Johannes Zuber; Veronika Sexl; Lukas Kenner; Wolfgang R Sperr; Peter Valent; Matthias Mayerhofer; Gregor Hoermann
Journal:  Blood       Date:  2016-11-16       Impact factor: 22.113

4.  KIT D816V and the cytokine storm in mastocytosis: production and role of interleukin-6.

Authors:  Peter Valent
Journal:  Haematologica       Date:  2020-01       Impact factor: 9.941

Review 5.  Endocrine manifestations of systemic mastocytosis in bone.

Authors:  Loren Wissner Greene; Kamyar Asadipooya; Patricia Freitas Corradi; Cem Akin
Journal:  Rev Endocr Metab Disord       Date:  2016-09       Impact factor: 6.514

Review 6.  Prevalence, pathogenesis, and treatment options for mastocytosis-related osteoporosis.

Authors:  M Rossini; R Zanotti; G Orsolini; G Tripi; O Viapiana; L Idolazzi; A Zamò; P Bonadonna; V Kunnathully; S Adami; D Gatti
Journal:  Osteoporos Int       Date:  2016-02-18       Impact factor: 4.507

7.  Osteoporosis Caused by Systemic Mastocytosis: Prevalence in a Cohort of 8392 Patients with Osteoporosis.

Authors:  Martin Gehlen; Niels Schmidt; Michael Pfeifer; Subathira Balasingam; Michael Schwarz-Eywill; Anna Maier; Mathias Werner; Heide Siggelkow
Journal:  Calcif Tissue Int       Date:  2021-07-05       Impact factor: 4.333

Review 8.  Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes.

Authors:  David González-de-Olano; Almudena Matito; Alberto Orfao; Luis Escribano
Journal:  F1000Res       Date:  2016-11-14

Review 9.  Cytokine Regulation of Microenvironmental Cells in Myeloproliferative Neoplasms.

Authors:  Gregor Hoermann; Georg Greiner; Peter Valent
Journal:  Mediators Inflamm       Date:  2015-10-12       Impact factor: 4.711

Review 10.  Does Allergy Break Bones? Osteoporosis and Its Connection to Allergy.

Authors:  Maria Maddalena Sirufo; Mariano Suppa; Lia Ginaldi; Massimo De Martinis
Journal:  Int J Mol Sci       Date:  2020-01-21       Impact factor: 5.923
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.